The PHARMAC boss was asked why PHARMAC funded a treatment for infantile-onset pompe disease when there are no New Zealand infants with pompe disease. …
Latest Video
New Stories
-
Clinical trials: Competition across countries and companies
December 13, 2019 - - Latest News -
High in fees low on performance measures
December 13, 2019 - - Latest News -
Deborah Monk: Recollections from APMA to Medicines Australia
December 13, 2019 - - Latest News -
Novartis launches Innovation Prize with a focus on MS
December 13, 2019 - - Latest News -
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News